Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan

Francesco Locatelli, Biff F. Palmer, Naoki Kashihara, Tevfik Ecder

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Objective: The purpose of this report is to review key data on the angiotensin receptor blocker (ARB) valsartan, along with data from several pivotal studies with other ARBs and angiotensin-converting enzyme (ACE) inhibitors, to highlight the beneficial class effects of renin-angiotensin- aldosterone system (RAAS) blockade throughout the renal continuum. Methods: The selection of articles was based on a search of PubMed for clinical trials published between 1997 (the year in which valsartan was approved for sale in the US) and 2009 that involved valsartan and reported effects on renal function, plus a select range of articles on other agents acting on the RAAS, including key guidance documents issued during this time. Summary: Valsartan has been studied extensively and is widely used for the management of hypertension. Data from clinical studies involving valsartan and other ARBs and ACE inhibitors provide evidence of an additional renal protective effect. This renal protection apparently arises from hemodynamic, endothelial, and antiinflammatory actions. Limitations: Given the extent of the available literature on this topic, this review included only a subset of available publications. This report may reflect inherent heterogeneity between patient populations from these studies and also incorporate the limitations of these individual publications. The inclusion of guidance documents from several organizations may have resulted in apparent minor conflicts in the approaches of the different groups.

Original languageEnglish (US)
Pages (from-to)2933-2949
Number of pages17
JournalCurrent Medical Research and Opinion
Volume25
Issue number12
DOIs
StatePublished - Dec 1 2009

    Fingerprint

Keywords

  • Angiotensin receptor blocker
  • Angiotensin-converting enzyme inhibitor
  • Kidney disease
  • RAAS blockade
  • Renal protection

ASJC Scopus subject areas

  • Medicine(all)

Cite this